Elute, Inc.

Elute, Inc. is a clinical-stage medical device company specializing in patented drug-eluting devices with controlled and sustained therapeutic release. The company focuses on orthopedic infections, developing novel bone void fillers (BVF) that deliver local antibiotic therapy over an 8-week period to treat periprosthetic joint infections. Their lead product, BonVie+™, is a resorbable bone graft substitute designed to support natural bone restoration while providing sustained antimicrobial coverage. The company's technology platform addresses unmet clinical needs in orthopedic surgery by combining bone regeneration with infection prevention and treatment. Elute has announced strategic partnerships, including collaboration with Spartan Medical, and is conducting clinical studies to validate their therapeutic approach. The company leverages proprietary drug-delivery technology to create products that enable patients to maintain active lifestyles post-surgical intervention.